InMed Pharmaceuticals Inc INM

Healthcare Cannabis

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.

NDAQ:INM - Post by User

InMed Pharmaceuticals Inc

Bullboard Posts

Comment by Jo1987on Mar 19, 2020 4:06pm

84 Views

Post# 30827956

RE:Cash burn

I think they have ~3 months for the share price to recover before a very unpleasant refinancing becomes necessary. That's of course still (easily) possible, but will require a relatively fast end of the current crisis.

I am going back and forth here if I should buy back in now. Intrinsically, the value of the company seems much higher to me than the current valuation. But right now it looks a bit like it's not in their own hands to fulfill that potential.

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading